6-氨基-2-[(4-甲基苄基)硫基]-4-嘧啶醇 | 166751-35-5

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 中文名称: 6-氨基-2-[(4-甲基苄基)硫基]-4-嘧啶醇
• 中文别名: 6-氨基-2-[(4-甲基苯甲基)硫烷基]嘧啶-4(1H)-酮
• 英文名称: 4-amino-2-(4-methylphenylmethylthio)-6-hydroxypyrimidine
• 英文别名: 6-Amino-2-[(4-methylbenzyl)thio]-4(3H)-pyrimidinone；4-amino-2-[(4-methylphenyl)methylsulfanyl]-1H-pyrimidin-6-one
• CAS: 166751-35-5
• 化学式: C₁₂H₁₃N₃OS
• mdl: MFCD03536215
• 分子量: 247.321
• InChiKey: OQQZKAPKMXBJSE-UHFFFAOYSA-N

物化性质

• 沸点：
  407.6±55.0 °C(Predicted)
• 密度：
  1.33±0.1 g/cm3(Predicted)
• 溶解度：
  13.1 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  92.8
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  6-氨基-2-[(4-甲基苄基)硫基]-4-嘧啶醇 生成 4-amino-6-chloro-2-(4-methylphenylmethylthio)-pyrimidine
  参考文献：
  名称：

  Pyrimidine-thioalkyl and alkylether compounds

  摘要：

  该发明涉及Formula I的嘧啶硫代烷基和烷基醚化合物，以及Formula IA的嘧啶硫代烷基和烷基醚化合物，即Formula I中R4选自-H或-NR15R16的基团，其中R15为-H，R16为-H，C1-C6烷基，-NH2或R15和R16一起与-N形成1-吡咯啉基、1-吗啉基或1-哌啶基；以及R6选自-H或卤素（优选-Cl）的基团，总体规定是R4和R6不能同时为-H；Formula IA的化合物在治疗HIV阳性个体中是有用的。

  公开号：

  EP1247804A1
• 作为产物：
  描述：

  4-甲基苄溴 、 6-氨基-2-硫脲嘧啶 生成 6-氨基-2-[(4-甲基苄基)硫基]-4-嘧啶醇
  参考文献：
  名称：

  Pyrimidine-thioalkyl and alkylether compounds

  摘要：

  该发明涉及Formula I的嘧啶硫代烷基和烷基醚化合物，以及Formula IA的嘧啶硫代烷基和烷基醚化合物，即Formula I中R4选自-H或-NR15R16的基团，其中R15为-H，R16为-H，C1-C6烷基，-NH2或R15和R16一起与-N形成1-吡咯啉基、1-吗啉基或1-哌啶基；以及R6选自-H或卤素（优选-Cl）的基团，总体规定是R4和R6不能同时为-H；Formula IA的化合物在治疗HIV阳性个体中是有用的。

  公开号：

  EP1247804A1

文献信息

• Alpha-substituted pyrimidine-thioalkyl and alkylether compounds
  申请人：PHARMACIA & UPJOHN COMPANY

  公开号：EP1449835A2

  公开（公告）日：2004-08-25

  The subject invention relates to pyrimidine-thioalkyl and alkylether compounds of Formula I and pyrimidine-thioalkyl and alkylethers of Formula IA, namely the compounds of Formula I where R4 is selected from the group consisting of -H or -NR15R16 where R15 is -H and R16 is -H, C1-C6 alkyl, -NH2 or R15 and R16 taken together with the -N form 1-pyrrolidino, 1-morpholino or 1-piperidino; and R6 is selected from the group consisting of -H, or halo (preferably -CI); with the overall provisio that R4 and R6 are not both -H; The compounds of Formula IA are useful in the treatment of individuals who are HIV positive being inhibitors of viral reverse transcriptase.

  本发明涉及式 I 的嘧啶硫烷基和烷基醚化合物 和式 IA 的嘧啶硫代烷基和烷基醚，即式 I 的化合物，其中 R4 选自由-H 或-NR15R16 组成的组，其中 R15 为-H，R16 为-H、C1-C6 烷基、-NH2 或 R15 和 R16 与-N 共同形成 1-吡咯烷基、1-吗啉基或 1-哌啶基；以及 R6 选自-H 或卤代物（最好是-CI）组成的组；但 R4 和 R6 不能都是-H； 式 IA 的化合物作为病毒逆转录酶的抑制剂，可用于治疗 HIV 阳性患者。
• Pyrimidine Thioethers:  A Novel Class of HIV-1 Reverse Transcriptase Inhibitors with Activity Against BHAP-Resistant HIV
  作者：Richard A. Nugent、Stephen T. Schlachter、Michael J. Murphy、Gary J. Cleek、Toni J. Poel、Donn G. Wishka、David R. Graber、Yoshihiko Yagi、Barbara J. Keiser、Robert A. Olmsted、Laurie A. Kopta、Steven M. Swaney、Susan M. Poppe、Joel Morris、W. Gary Tarpley、Richard C. Thomas

  DOI：10.1021/jm9800806

  日期：1998.9.1

  A series of pyrimidine thioethers was synthesized and evaluated for inhibitory properties against wild-type HIV-1 reverse transcriptase (RT) and an RT carrying the resistance-conferring mutation P236L. Modifications of both the pyrimidine and the functionality attached through the thioether yielded several analogues, which demonstrated activity against both enzyme types, with IC50 values as low as 190 nM against wild-type and 66 nM against P236L RT. Evaluation of a select number of pyrimidine thioethers in cell culture showed that these compounds have excellent activity against HIV-1(IIIB)-WT and retain good activity against a laboratory-derived HIV-1(MF) delavirdine-resistant variant.
• Discovery and optimization of aminopyrimidinones as potent and state-dependent Nav1.7 antagonists
  作者：Hanh Nho Nguyen、Howie Bregman、John L. Buchanan、Bingfan Du、Elma Feric、Liyue Huang、Xingwen Li、Joseph Ligutti、Dong Liu、Annika B. Malmberg、David J. Matson、Jeff S. McDermott、Vinod F. Patel、Ben Wilenkin、Anruo Zou、Stefan I. McDonough、Erin F. DiMauro

  DOI：10.1016/j.bmcl.2011.11.111

  日期：2012.1

  Clinical genetic data have shown that the product of the SCN9A gene, voltage-gated sodium ion channel Nav1.7, is a key control point for pain perception and a possible target for a next generation of analgesics. Sodium channels, however, historically have been difficult drug targets, and many of the existing structure-activity relationships (SAR) have been defined on pharmacologically modified channels with indirect reporter assays. Herein we describe the discovery, optimization, and SAR of potent aminopyrimidinone Nav1.7 antagonists using electrophysiology-based assays that measure the ligand-receptor interaction directly. Within this series, rapid functionalization at the polysubstituted aminopyrimidinone head group enabled exploration of SAR and of pharmacokinetic properties. Lead optimized N-Me-aminopyrimidinone 9 exhibited improved Nav1.7 potency, minimal off-target hERG liability, and improved rat PK properties. (C) 2011 Elsevier Ltd. All rights reserved.
• COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER
  申请人：TOMKINSON Alan E.

  公开号：US20100099683A1

  公开（公告）日：2010-04-22

  Methods for treating cancer using compounds that inhibit human DNA ligases. Methods for using compounds that inhibit human DNA ligases to provide insights into the reaction mechanisms of human DNA ligases, for example to identify the human DNA ligase involved in different DNA repair pathways. Screening methods for compounds that inhibit human DNA ligases.
• Compounds that inhibit human DNA ligases and methods of treating cancer
  申请人：University of Maryland, Baltimore

  公开号：US20140113891A1

  公开（公告）日：2014-04-24

  Methods for treating cancer using compounds that inhibit human DNA ligases. Methods for using compounds that inhibit human DNA ligases to provide insights into the reaction mechanisms of human DNA ligases, for example to identify the human DNA ligase involved in different DNA repair pathways. Screening methods for compounds that inhibit human DNA ligases.